Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer

Phase 1Actinium (²²⁵Ac) rhPSMA-10.1 InjectionPositive

AI Analysis

Summary

Blue Earth Therapeutics announced the first participant dosed in a Phase 1 clinical trial of Actinium (²²⁵Ac) rhPSMA-10.1 Injection for metastatic castration-resistant prostate cancer, a UCL-sponsored study evaluating safety, tolerability, and radiation dosimetry.

Clinical Trial Data

Phase

Phase 1

Outcome Details

first participant dosed

Importance:5/10

Sentiment:

0.60

Phase 1radiopharmaceuticalprostate canceralpha-emitterPSMA-targetedradiohybrid platform

Related Companies

$ONT.L $ETST $DRTSW $TRAX

Read the original article

Published by PR Newswire Biotech on July 9, 2026 10:01 AM

Read Original